Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.
After decades of stagnation, a renewed push in tuberculosis research is expanding the drug and vaccine pipeline to bring one of humanity’s oldest and deadliest infectious diseases under control.
In the phase 3 EVOKE(+) trials, semaglutide did not slow clinical progression of Alzheimer’s disease, but the findings provide new insights in the ongoing quest for treatments.
ProtAIDe-Dx is a deep joint-learning model that uses plasma proteomics to provide simultaneous probabilistic diagnoses across six conditions associated with aging.
Benralizumab (an anti-IL-5 receptor α antibody), compared to placebo, significantly reduced the risk of first flare in patients with hypereosinophilic syndrome.
We have systematically mapped the exposome onto health and disease risk to replace pervasive fragmented research. Although exposure associations are modest, these reproducible patterns reflect how our surroundings can affect our bodies and collectively shape our health. Our atlas provides a blueprint for integrating and evaluating environmental factors into precision medicine.
Despite major global declines in ischemic heart disease mortality, the influence of suboptimal diet remains substantial and unevenly distributed across populations. This study quantifies the contributions of individual dietary components to ischemic heart disease over more than 30 years and uncovers persistent disparities by age, sex, region and socioeconomic status.
Genetic sequencing data from a large cohort of Latin American individuals showed that the genes that are significantly associated with the risk of autism extensively overlapped with those found in genome-wide sequencing studies in people of predominantly European ancestry.
A phase 1 study assessing the safety of placenta-derived stem cell therapy for in utero myelomeningocele repair shows promise for treating this severe form of spina bifida.
In a phase 1b trial, patients with treatment-naive metastatic pancreatic adenocarcinoma received the CD73 inhibitor quemliclustat plus gemcitabine and nabpaclitaxel with or without the anti-PD1 antibody zimberelimab, showing encouraging clinical response rates and survival in quemliclustat-treated patients.
Global Burden of Disease analysis found that in 2023, suboptimal diet was estimated to be responsible for 4 million deaths and 97 million morbidity burdens from ischemic heart disease.
Genetic analyses in more than 15,000 individuals from across the Americas, including individuals with autism and family members, define the genetic landscape of autism in Latin American populations and identify significant overlap with other ancestries.
In a randomized trial, treatment of patients with heart failure with an antibody designed to activate the guanylate cyclase receptor NPR1 led to an unexpected increase in NT-proBNP levels and worsening heart failure events compared with the control, prompting termination of the trial.
In a randomized trial enrolling Black adults residing in food deserts in Boston, Massachusetts, who were undergoing treatment for hypertension, home-delivery for 3 months of groceries designed to provide a low-sodium diet, together with dietician counseling, reduced blood pressure beyond a monetary stipend, an effect that was maintained for an additional 3 months after the intervention ended.
Time-restricted eating (TRE) and daily calorie restriction both led to significant weight loss in women with polycystic ovary syndrome compared to controls. Thus, TRE is a safe and effective alternative to calorie restriction for weight management in this population.
In the nonpivotal stage 1 of the randomized phase 3 PRESERVE-003 trial, patients with immunochemotherapy-resistant metastatic squamous non-small cell lung cancer without actionable genomic alterations treated with the next-generation, pH-sensitive anti-CTLA-4 agent gotistobart had encouraging overall survival outcomes compared to docetaxel.
